Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Major Bank Ratings | Morgan Stanley: Macau gaming revenue expected to grow by 6% this year, Macau gaming stocks likely to underperform the broader market in the short term

Major Bank Ratings | Morgan Stanley: Macau gaming revenue expected to grow by 6% this year, Macau gaming stocks likely to underperform the broader market in the short term

格隆汇格隆汇2026/03/19 03:12
Show original
格隆汇 March 19|Morgan Stanley released a report, forecasting a 6% growth in Macau gaming revenue this year, with EBITDA rising only 2%, which is below market expectations and weaker year-on-year. Due to the base effect impacting gaming revenue in the second half of the year, growth will slow down, and the core mass market remains persistently weak. Additionally, the level of promotional offers in the industry is rising, along with continued non-gaming expenditures. As the focus is on the premium mass market, cost pressures (especially reinvestment) are structural. Downward revisions in market earnings estimates will put pressure on this year's EBITDA forecasts. The bank expects Macau gaming stocks to underperform the broader market in the short term, and has downgraded its industry view from "attractive" to "in line with expectations"; it anticipates that gaming revenue growth will slow year-on-year starting in May, with EBITDA negative growth recorded in the second and third quarters.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53